APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Disease Aerosol Delivery Devices

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pulmonary Disease Aerosol Delivery Devices Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174029940329 December 2025191 pages

Choose your research edition.

Industry ResearchPulmonary Disease Aerosol Delivery Devices Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Disease Aerosol Delivery Devices Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Pulmonary Disease Aerosol Delivery Devices Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Disease Aerosol Delivery Devices Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Disease Aerosol Delivery Devices Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Pulmonary Disease Aerosol Delivery Devices market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Disease Aerosol Delivery Devices include Novartis, Merck, Viatris, GlaxoSmithKline (GSK), AstraZeneca, Vectura, Teva Pharmaceutical Industries, PARI International and OMRON, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Disease Aerosol Delivery Devices market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Disease Aerosol Delivery Devices and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Disease Aerosol Delivery Devices sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Disease Aerosol Delivery Devices market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Disease Aerosol Delivery Devices Segment by Company

Novartis

Merck

Viatris

GlaxoSmithKline (GSK)

AstraZeneca

Vectura

Teva Pharmaceutical Industries

PARI International

OMRON

Monaghan Medical

Koninklijke Philips

H&T Presspart

Chiesi Farmaceutici

Boehringer Ingelheim

AptarGroup

Pulmonary Disease Aerosol Delivery Devices Segment by Type

Metered- dose Inhalers

Dry-powder Inhalers

Nebulizers

Pulmonary Disease Aerosol Delivery Devices Segment by Application

Asthma

Idiopathic Pulmonary Fibrosis (IPF)

Cystic Fibrosis (CF)

Chronic Obstructive Pulmonary Disease (COPD)

Others

Pulmonary Disease Aerosol Delivery Devices Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Disease Aerosol Delivery Devices market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Disease Aerosol Delivery Devices and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Disease Aerosol Delivery Devices.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Disease Aerosol Delivery Devices market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Disease Aerosol Delivery Devices manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pulmonary Disease Aerosol Delivery Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pulmonary Disease Aerosol Delivery Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Disease Aerosol Delivery Devices Industry Trends Table 2. Pulmonary Disease Aerosol Delivery Devices Industry Drivers Table 3. Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges Table 4. Pulmonary Disease Aerosol Delivery Devices Industry Restraints Table 5. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pulmonary Disease Aerosol Delivery Devices Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Manufacturers Table 9. Global Pulmonary Disease Aerosol Delivery Devices Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pulmonary Disease Aerosol Delivery Devices Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pulmonary Disease Aerosol Delivery Devices Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pulmonary Disease Aerosol Delivery Devices Manufacturers, Product Type & Application Table 13. Global Pulmonary Disease Aerosol Delivery Devices Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Disease Aerosol Delivery Devices by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Metered- dose Inhalers Table 17. Major Manufacturers of Dry-powder Inhalers Table 18. Major Manufacturers of Nebulizers Table 19. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2026) & (K Units) Table 21. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2027-2032) & (K Units) Table 22. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2026) Table 23. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2027-2032) Table 24. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021-2026) & (K Units) Table 26. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2027-2032) & (K Units) Table 27. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2026) Table 28. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Asthma Table 30. Major Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Table 31. Major Manufacturers of Cystic Fibrosis (CF) Table 32. Major Manufacturers of Chronic Obstructive Pulmonary Disease (COPD) Table 33. Major Manufacturers of Others Table 34. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2026) & (K Units) Table 36. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2027-2032) & (K Units) Table 37. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2026) Table 38. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2027-2032) Table 39. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021-2026) & (K Units) Table 41. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2027-2032) & (K Units) Table 42. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2026) Table 43. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2027-2032) Table 44. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2026) & (K Units) Table 46. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region (2021-2026) Table 47. Global Pulmonary Disease Aerosol Delivery Devices Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Pulmonary Disease Aerosol Delivery Devices Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 51. North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 52. Europe Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 54. Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 61. Global Pulmonary Disease Aerosol Delivery Devices Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region (2021-2026) Table 65. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region (2027-2032) Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 70. Novartis Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 75. Merck Recent Development Table 76. Viatris Company Information Table 77. Viatris Business Overview Table 78. Viatris Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 80. Viatris Recent Development Table 81. GlaxoSmithKline (GSK) Company Information Table 82. GlaxoSmithKline (GSK) Business Overview Table 83. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 85. GlaxoSmithKline (GSK) Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Vectura Company Information Table 92. Vectura Business Overview Table 93. Vectura Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 95. Vectura Recent Development Table 96. Teva Pharmaceutical Industries Company Information Table 97. Teva Pharmaceutical Industries Business Overview Table 98. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 100. Teva Pharmaceutical Industries Recent Development Table 101. PARI International Company Information Table 102. PARI International Business Overview Table 103. PARI International Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 105. PARI International Recent Development Table 106. OMRON Company Information Table 107. OMRON Business Overview Table 108. OMRON Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 110. OMRON Recent Development Table 111. Monaghan Medical Company Information Table 112. Monaghan Medical Business Overview Table 113. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 115. Monaghan Medical Recent Development Table 116. Koninklijke Philips Company Information Table 117. Koninklijke Philips Business Overview Table 118. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 120. Koninklijke Philips Recent Development Table 121. H&T Presspart Company Information Table 122. H&T Presspart Business Overview Table 123. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 125. H&T Presspart Recent Development Table 126. Chiesi Farmaceutici Company Information Table 127. Chiesi Farmaceutici Business Overview Table 128. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 130. Chiesi Farmaceutici Recent Development Table 131. Boehringer Ingelheim Company Information Table 132. Boehringer Ingelheim Business Overview Table 133. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 135. Boehringer Ingelheim Recent Development Table 136. AptarGroup Company Information Table 137. AptarGroup Business Overview Table 138. AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 140. AptarGroup Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Pulmonary Disease Aerosol Delivery Devices Distributors List Table 144. Pulmonary Disease Aerosol Delivery Devices Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Pulmonary Disease Aerosol Delivery Devices Product Image Figure 2. Global Pulmonary Disease Aerosol Delivery Devices Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Disease Aerosol Delivery Devices Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Disease Aerosol Delivery Devices Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Disease Aerosol Delivery Devices Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pulmonary Disease Aerosol Delivery Devices Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Metered- dose Inhalers Image Figure 9. Dry-powder Inhalers Image Figure 10. Nebulizers Image Figure 11. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2032) Figure 14. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2032) Figure 17. Asthma Image Figure 18. Idiopathic Pulmonary Fibrosis (IPF) Image Figure 19. Cystic Fibrosis (CF) Image Figure 20. Chronic Obstructive Pulmonary Disease (COPD) Image Figure 21. Others Image Figure 22. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2032) Figure 25. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2032) Figure 28. North America Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 30. U.S. Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 35. Germany Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 42. China Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 50. Brazil Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Pulmonary Disease Aerosol Delivery Devices Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Pulmonary Disease Aerosol Delivery Devices Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032) & (US$ Million) Figure 61. North America Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032) & (US$ Million) Figure 63. Europe Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Pulmonary Disease Aerosol Delivery Devices Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Pulmonary Disease Aerosol Delivery Devices Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Metered- dose Inhalers
  • Dry-powder Inhalers
  • Nebulizers
Applications
  • Asthma
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Cystic Fibrosis (CF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
Companies covered
  • Novartis
  • Merck
  • Viatris
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Vectura
  • Teva Pharmaceutical Industries
  • PARI International
  • OMRON
  • Monaghan Medical
  • Koninklijke Philips
  • H&T Presspart
  • Chiesi Farmaceutici
  • Boehringer Ingelheim
  • AptarGroup

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Disease Aerosol Delivery Devices Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Disease Aerosol Delivery Devices Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pulmonary Disease Aerosol Delivery Devices Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pulmonary Disease Aerosol Delivery Devices Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pulmonary Disease Aerosol Delivery Devices Market Dynamics
  1. 2.1 Pulmonary Disease Aerosol Delivery Devices Industry Trends
  2. 2.2 Pulmonary Disease Aerosol Delivery Devices Industry Drivers
  3. 2.3 Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges
  4. 2.4 Pulmonary Disease Aerosol Delivery Devices Industry Restraints
3 Pulmonary Disease Aerosol Delivery Devices Market by Manufacturers
  1. 3.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pulmonary Disease Aerosol Delivery Devices Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pulmonary Disease Aerosol Delivery Devices Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Disease Aerosol Delivery Devices Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pulmonary Disease Aerosol Delivery Devices Manufacturers, Product Type & Application
  7. 3.7 Global Pulmonary Disease Aerosol Delivery Devices Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Disease Aerosol Delivery Devices Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Disease Aerosol Delivery Devices Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Disease Aerosol Delivery Devices Tier 1, Tier 2, and Tier 3
4 Pulmonary Disease Aerosol Delivery Devices Market by Type
  1. 4.1 Pulmonary Disease Aerosol Delivery Devices Type Introduction
  2. 4.1.1 Metered- dose Inhalers
  3. 4.1.2 Dry-powder Inhalers
  4. 4.1.3 Nebulizers
  5. 4.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type
  6. 4.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type
  10. 4.3.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2032)
5 Pulmonary Disease Aerosol Delivery Devices Market by Application
  1. 5.1 Pulmonary Disease Aerosol Delivery Devices Application Introduction
  2. 5.1.1 Asthma
  3. 5.1.2 Idiopathic Pulmonary Fibrosis (IPF)
  4. 5.1.3 Cystic Fibrosis (CF)
  5. 5.1.4 Chronic Obstructive Pulmonary Disease (COPD)
  6. 5.1.5 Others
  7. 5.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application
  8. 5.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2032)
  10. 5.2.3 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2032)
  11. 5.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application
  12. 5.3.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021-2032)
  14. 5.3.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2032)
6 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region
  1. 6.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2026)
  4. 6.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region
  1. 7.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region
  2. 7.1.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2021-2026)
  4. 7.1.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2027-2032)
  5. 7.1.4 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032)
  8. 7.2.2 North America Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032)
  11. 7.3.2 Europe Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 GlaxoSmithKline (GSK)
  20. 8.4.1 GlaxoSmithKline (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  24. 8.4.5 GlaxoSmithKline (GSK) Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Vectura
  32. 8.6.1 Vectura Company Information
  33. 8.6.2 Vectura Business Overview
  34. 8.6.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  36. 8.6.5 Vectura Recent Developments
  37. 8.7 Teva Pharmaceutical Industries
  38. 8.7.1 Teva Pharmaceutical Industries Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 8.8 PARI International
  44. 8.8.1 PARI International Company Information
  45. 8.8.2 PARI International Business Overview
  46. 8.8.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  48. 8.8.5 PARI International Recent Developments
  49. 8.9 OMRON
  50. 8.9.1 OMRON Company Information
  51. 8.9.2 OMRON Business Overview
  52. 8.9.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  54. 8.9.5 OMRON Recent Developments
  55. 8.10 Monaghan Medical
  56. 8.10.1 Monaghan Medical Company Information
  57. 8.10.2 Monaghan Medical Business Overview
  58. 8.10.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  60. 8.10.5 Monaghan Medical Recent Developments
  61. 8.11 Koninklijke Philips
  62. 8.11.1 Koninklijke Philips Company Information
  63. 8.11.2 Koninklijke Philips Business Overview
  64. 8.11.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  66. 8.11.5 Koninklijke Philips Recent Developments
  67. 8.12 H&T Presspart
  68. 8.12.1 H&T Presspart Company Information
  69. 8.12.2 H&T Presspart Business Overview
  70. 8.12.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  72. 8.12.5 H&T Presspart Recent Developments
  73. 8.13 Chiesi Farmaceutici
  74. 8.13.1 Chiesi Farmaceutici Company Information
  75. 8.13.2 Chiesi Farmaceutici Business Overview
  76. 8.13.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  78. 8.13.5 Chiesi Farmaceutici Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 AptarGroup
  86. 8.15.1 AptarGroup Company Information
  87. 8.15.2 AptarGroup Business Overview
  88. 8.15.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  90. 8.15.5 AptarGroup Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Disease Aerosol Delivery Devices Value Chain Analysis
  2. 9.1.1 Pulmonary Disease Aerosol Delivery Devices Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Disease Aerosol Delivery Devices Production Mode & Process
  6. 9.2 Pulmonary Disease Aerosol Delivery Devices Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Disease Aerosol Delivery Devices Distributors
  9. 9.2.3 Pulmonary Disease Aerosol Delivery Devices Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst